Extracorporeal Circulation: Prevention and Management of Complications

  • J. O. C. AulerJr.
Conference paper


The development of extracorporeal circulation (ECC) has indubitably been extremely important in the progress of cardiac surgery. The possibility of bypassing blood outside the heart and lungs, pumping oxygenated blood from the venous system directly to the arterial system, has permitted all types of cardiac surgery. Extracorporeal circulation has also allowed surgical approaches to complex diseases, such as correction of thoracic aortic aneurysms, resection of renal cell carcinoma, treatment of neurobasilar aneurysms, lung transplantation, and thrombo-endarterectomy of pulmonary arteries. Others uses of ECC include veno-venous bypass in liver transplantation, in acute respiratory failure as part of a “lung protective strategy”, in acute pulmonary hypertension of newborn, in high-risk angioplasty patients and ventricular assistance. Ideally, to replace the functions of the heart and lungs cardiopulmonary bypass (CPB) should achieve several aims, with minimal risks and interferences to normal physiology. The main purpose of CPB is to maintain systemic perfusion with adequate oxygen transport and carbon dioxide elimination, preserving homeostasis while the heart and lungs are not providing these functions. All extracorporeal circuits that return blood to the patient require the incorporation of some kind of pumping device. This pumping mechanism may occur by various basic principles of fluid movement which include positive displacement, centrifugal vortexing and pneumatic and electrical pulsation. Positive displacement pumps have been largely used in ECC since it was proposed by Gibbon [11. The second type of pump device used in ECC is the centrifugal pump or resistance-dependent pump. This system works by the addition of kinetic energy to the fluid through the forced rotation of an impeller or cone. A centrifugal pump was proposed for clinical use in 1976, and since then its acceptance in CPB has increased progressively. The other components of cardiopulmonary circuitry are the oxygenators, heat exchangers, cannulae and tubing, and the cardioplegia delivery system. The oxygenators have the main function of gas transfer, and, at the same time, they should have a low rate of bioreactivity. Oxygenators utilized in CPB are currently divided into two classes based on the method of gas exchange: bubble and membrane oxygenators. Although more complex in design, membrane oxygenators are much more used nowadays in routine CPB, mainly because this is thought to be a much safer system than bubble oxygenators, which cause gaseous microemboli and induce hematologic damage to the formed elements of blood [2, 3]. As described below, it has been known for several years that CPB triggers an inflammatory response that can lead to the development of postoperative organ dysfunction. This response may occur with both oxygenators, bubble and membrane [4], but the use of bubble oxygenators has been shown to be able to induce a greater inflammatory response when compared to membrane oxygenators. Bubble oxygenators seem to be responsible for greater complement activation and lung leukocyte sequestration when compared to membrane [5]. Another study demonstrated higher levels of intercellular adhesion molecule-1 (sICAM-1) in the blood during use of bubble oxygenators when compared to membrane [6].


Cardiopulmonary Bypass Centrifugal Pump Extracorporeal Circulation Tissue Factor Pathway Inhibitor Thoracic Aortic Aneurysm 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gibbon JH (1937) Artificial maintenance of circulation during experimental occlusion of pulmonary artery. Arch Surg 34: 1105–1131CrossRefGoogle Scholar
  2. 2.
    Pearson DT (1990) Gas exchange: bubble and membrane oxygenators. Semin Thorac Cardiovasc Surg 2: 313–319PubMedGoogle Scholar
  3. 3.
    Boers M, Van den Dungen JM, Karliczeck GF et al (1983) Two membrane oxygenators and bubble. A clinical comparison. Ann Thorac Surg 35: 455–462Google Scholar
  4. 4.
    Moat NE, Shore DF, Evans TW (1993) Organ dysfunction and cardiopulmonary bypass: the role of complement and complement regulatory proteins. Eur J Cardiothorac Surg 7: 563–573PubMedCrossRefGoogle Scholar
  5. 5.
    Cavarochi NC, Pluth JR, Schaff HV et al (1986) Complement activation during cardiopulmonary bypass. J Thorac Cardiovasc Surg 91: 252–258Google Scholar
  6. 6.
    Gillinov AM, Bator JM, Zehr KJ et al (1993) Neutrophil adhesion molecule expression during cardiopulmonary bypass with bubble and membrane oxygenators. Ann Thorac Surg 56: 847–853PubMedCrossRefGoogle Scholar
  7. 7.
    Sudhaman DA (1991) Accidental hyperperfusion of the left carotid artery during CPB (letter). J Cardiothorac Vasc Anesth 5: 100–101PubMedCrossRefGoogle Scholar
  8. 8.
    Watson BG (1983) Unilateral cold neck. A new sign of misplacement of the aortic cannula during cardiopulmonary bypass. Anaesthesia 38: 659–661PubMedGoogle Scholar
  9. 9.
    Murphy DA, Craver JM, Jones EL et al (1983) Recognition and management of ascending aortic dissection complicating cardiac surgical operations. J Thorac Cardiovasc Surg 85: 247–256PubMedGoogle Scholar
  10. 10.
    Bayindir O, Paker T, Akpinar B et al (1991) Case 6–1991: A 58-year-old man had a massive air embolism during cardiopulmonary bypass [clinical conference]. J Cardiothorac Vasc Anesth 5: 627–634PubMedCrossRefGoogle Scholar
  11. 11.
    Armon C, Deschamps C, Adkinson C et al (1991) Hyperbaric treatment of cerebral air embolism sustained during an open heart surgical procedure. Mayo Clin Proc 66: 565–571PubMedCrossRefGoogle Scholar
  12. 12.
    Butler J, Rocker GM, Westaby S (1993) Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 55: 552–559PubMedCrossRefGoogle Scholar
  13. 13.
    Ellison N, Behar M, MacVaugh H III, Marshall BE (1980) Bradykinin, plasma protein fraction and hypotension. Ann Thorac Surg 29: 15–19PubMedCrossRefGoogle Scholar
  14. 14.
    Parker DJ, Cantrell JW, Karp RB et al (1972) Changes in serum complement and immunoglobulins following cardiopulmonary bypass. Surgery 71: 824–827PubMedGoogle Scholar
  15. 15.
    Kirklin JK, Westaby S, Blackstone EH et al (1983) Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 86: 845–857PubMedGoogle Scholar
  16. 16.
    Fosse E, Mollnes TE, Ingvaldsen B (1986) Complement activation during major operations without cardiopulmonary bypass. J Thorac Cardiovasc Surg 93: 860–866Google Scholar
  17. 17.
    Carlos TM, Harlan JM (1990) Membrane proteins involved in phagocyte adherence to endothelium. Immunol Rev 114: 5–28PubMedCrossRefGoogle Scholar
  18. 18.
    Dreyer WJ, Michael LH, Nguyen T et al (1992) Neutrophil-mediated pulmonary injury in a canine model of cardiopulmonary bypass: evidence for a CD 18-dependent mechanism. Circulation 86[Suppl I1: I629Google Scholar
  19. 19.
    Wilson I, Gillinov AM, Curtis WE et al (1993) Inhibition of neutrophil adherence improves post-ischemic ventricular performance of the neonatal heart. Circulation 88: 372–379CrossRefGoogle Scholar
  20. 20.
    Downing SW, Edmunds LH Jr (1992) Release of vasoactive substances during cardiopulmonary bypass. Ann Thorac Surg 54: 1236–1243PubMedCrossRefGoogle Scholar
  21. 21.
    Ruvuolo G, Greco E, Speziale G et al (1994) Nitric oxide formation during cardiopulmonary bypass. Ann Thorac Surg 57: 1055–1056CrossRefGoogle Scholar
  22. 22.
    Matheis G, Sherman MP, Buckberg GD et al (1992) Role of 1-arginine-nitric oxide pathway in myocardial re-oxygenation injury. Am J Physiol 262: H616 - H620PubMedGoogle Scholar
  23. 23.
    Delgado R, Rojas A, Glaria LA et al (1995) Calcium-independent nitric oxide synthase activity in human lung after cardiopulmonary bypass. Thorax 50: 403–404PubMedCrossRefGoogle Scholar
  24. 24.
    Jansen NJG, van Oeveren W, Gu YJ et al (1992) Endotoxin release and tumor necrosis factor formation during cardiopulmonary bypass. Ann Thorac Surg 54: 744–748PubMedCrossRefGoogle Scholar
  25. 25.
    Shandelya SML, Kuppusamy P, Weisfeldt ML et al (1993) Evaluation of the role of polymorphonuclear leukocytes on contractile function in myocardial reperfusion injury: evidence for plasma-mediated leukocyte activation. Circulation 87: 536–546PubMedCrossRefGoogle Scholar
  26. 26.
    Boyle EM Jr, Pohlman TH, Johnson MC et al (1997) Endothelial cell injury in cardiovascular surgery: the systemic inflammatory response. Ann Thorac Surg 63: 277–294PubMedCrossRefGoogle Scholar
  27. 27.
    Hall RI, Smith SM, Graeme R (1997) The systemic inflammatory response to cardiopulmonary bypass: pathophysiological, therapeutic and pharmacological considerations. Anesth Analg 85: 766–782PubMedGoogle Scholar
  28. 28.
    Fransen E, Maessen J, Dentener M et al (1998) Systemic inflammation present in patients undergoing CABG without extracorporeal circulation. Chest 113: 1290–1295PubMedCrossRefGoogle Scholar
  29. 29.
    Moat NE, Shore DF, Evans TW (1993) Organ dysfunction and cardiopulmonary bypass: the role of complement and complement regulatory proteins. Eur J Cardiothorac Surg 7: 563–573PubMedCrossRefGoogle Scholar
  30. 30.
    Johnson D, Thompson D, Hurst T et al (1994) Neutrophil mediated acute lung injury after extracorporeal circulation. J Thorac Cardiovasc Surg 107: 1193–1202PubMedGoogle Scholar
  31. 31.
    Redmond JM, Gillinov AM, Sturat RS et al (1993) Heparin-coated bypass circuits reduce pulmonary injury. Ann Thorac Surg 56: 474–479PubMedCrossRefGoogle Scholar
  32. 32.
    Martinez-Pellus AE, Merino P, Bru M et al (1993) Can selective digestive decontamination avoid the endotoxemia, and cytokine activation promoted by cardiopulmonary bypass? Crit Care Med 21: 1684–1691PubMedCrossRefGoogle Scholar
  33. 33.
    Niazi Z, Flodin P, Joyce L et al (1979) Effects of glucocorticoids in patients undergoing coronary artery bypass surgery. Chest 76: 262–268PubMedCrossRefGoogle Scholar
  34. 34.
    Andersen LW, Baek L, Thomsen BS et al (1989) The effect of methylprednisolone on endotoxemia and complement activation during cardiac surgery. J Cardiothorac Anesth 3: 544–549PubMedCrossRefGoogle Scholar
  35. 35.
    Boldt J, Osmer C, Schindler E et al (1995) Circulating adhesion molecules in cardiac operations: influence of high dose aprotinin. Ann Thorac Surg 59: 100–105PubMedCrossRefGoogle Scholar
  36. 36.
    Edmunds LI-I (1995) Why cardiopulmonary bypass makes patients sick: Strategies to control the blood-synthetic surface interface. Adv Card Surg 6: 131–167PubMedGoogle Scholar
  37. 37.
    Broze GJ (1995) Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagul Fibrinolysis 6[Suppl 11:57-S 13Google Scholar
  38. 38.
    Cardigan AR, Mackie IJ, Machin SJ (1997) Hemostatic endothelial interactions: a potential anticoagulant role of the endothelium in the pulmonary circulation during cardiac surgery. J Cardiothorac Vasc Anesth 11: 329–336PubMedCrossRefGoogle Scholar
  39. 39.
    Menasché P, Peynet J, Lariviere J et al (1994) Does normothermia during cardiopulmonary bypass increase neutrophil-endothelium interactions? Circulation 90: I1275 - I1279Google Scholar
  40. 40.
    Elliot MJ (1993) Ultrafiltration and modified ultrafiltration in pediatric open heart operations. Ann Thorac Surg 56: 1518–1522CrossRefGoogle Scholar
  41. 41.
    Journois D, Pouard P, Greeley WJ et al (1994) Hemofiltration during cardiopulmonary bypass in pediatric cardiac surgery. Anesthesiology 81: 1181–1189PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2000

Authors and Affiliations

  • J. O. C. AulerJr.

There are no affiliations available

Personalised recommendations